amador bioscience-png

Clinical Pharmacology to Accelerate Global Drug Development

The clinical development of your new drugs is focused, faster, and more efficient in our care. We provide comprehensive biometrics (SAS, NCA) and pharmacometrics services. Our global team performs advanced translational and clinical modeling & simulations to expediate the development of novel therapeutics across all technology platforms.

A2PG is now fully integrated into our global clinical pharmacology team.

Talk to an Expert
Noncompartmental PK/TK Analysis & Reporting GLP Compliance (21 CFR Part 11); Critical to characterize PK properties early and efficiently; Key component of toxicology reports and clinical study reports. Statistical Programming

Generating SEND & SDTM datasets; SAS programming; creating tables, listings and figures for clinical study reports and regulatory submissions.
Translational Modeling & Simulations Quantitative integration of nonclinical pharmacology, DMPK and toxicology data for clinical PKPD projection and first-in-human dose recommendation. Pharmacometrics Population PKPD modeling and exposure-response analyses of clinical endpoints for optimal dose selection, rational trial designs, PK/efficacy/safety covariate analyses and regulatory submissions. Quantitative Systems Pharmacology (QSP) Mechanistic, multi-scale systems model to elucidate the connections between the target, pathway, disease, physiology and therapeutic intervention for optimization. Expert Consultation

To leverage our extenstive industry experience for efficient trial designs, rational decision making and effective regulatory interactions.

How Can We Help?

Learn how we can help you make informed decisions about your clinical program. Our team of scientists provides the data and expertise you need to meet regulatory standards and make go/no-go decisions faster.

Let's Get Started

Accelerate your Drug Development by Leveraging Our Years of Experience

With our leaders' extensive industry experience, you can rely on us for efficient trial design, expedited clinical development and successful regulatory approvals of novel drugs in global markets.



4-1 Model Informed Drug Development (MIDD) We develop comprehensive pharmacostatistical models to describe and explain observed PK, efficacy and safety clinical data, followed by projections of various clinical treatment scenaiors via simulations, to guide or assist rational clinical decision making (optimal dose selection, efficient trial design, indication and patient selections, regulatory interactions and NDA/BLA/MAA filings). Website Photos (6) Global Drug Development and Launch Our clinical pharmacology teams in the US, China and EU, along with local regulatory, clinical and BioA business units, offer comprehensive support for global drug development and marketing approvals.

Have a Question?

It's easy to talk to one of our experts. Get in touch with your questions or comments and a member of our team will get back to you directly.

Talk to an expert